Chapter 22: Problem 12
What limits the use of differences in restriction enzyme sites as a way of detecting point mutations in human genes?
Chapter 22: Problem 12
What limits the use of differences in restriction enzyme sites as a way of detecting point mutations in human genes?
All the tools & learning materials you need for study success - in one app.
Get started for freeThe family of a sixth-grade boy in Palo Alto, California, was informed by school administrators that he would have to transfer out of his middle school because they believed his mutation of the \(C F T R,\) which does not produce any symptoms associated with cystic fibrosis, posed a risk to other students at the school who have cystic fibrosis. After missing 11 days of school, a settlement was reached to have the boy return to school. Based on what you know about GINA, the Genetic Information Nondiscrimination Act, what ethical problems might you associate with this example?
An unapproved form of gene therapy, known as enhancement gene therapy, can create considerable ethical dilemmas. Why?
In this chapter, we focused on a number of interesting applications of genetic engineering, genomics, and biotechnology. At the same time, we found many opportunities to consider the methods and reasoning by which much of this information was acquired. From the explanations given in the chapter, what answers would you propose to the following fundamental questions: (a) What experimental evidence confirms that we have introduced a useful gene into a transgenic organism and that it performs as we anticipate? (b) How can we use DNA analysis to determine that a human fetus has sickle- cell anemia? (c) How can DNA microarray analysis be used to identify specific genes that are being expressed in a specific tissue? (d) How are GWAS carried out, and what information do they provide? (e) What are some of the technical reasons why gene therapy is difficult to carry out effectively?
Sequencing the human genome and the development of microarray technology promise to improve our understanding of normal and abnormal cell behavior. How are microarrays dramatically changing our understanding of complex diseases such as cancer?
(a) Would you agree with Judge Sweet's ruling to invalidate the patenting of the \(B R C A 1\) and \(B R C A 2\) genes? If you were asked to judge the patenting of the direct-to-consumer test for the \(B R C A 1\) and \(B R C A 2\) genes, how would you rule? (b) \(\mathrm{J}\). Craig Venter has filed a patent application for his "firstever human made life form." This patent is designed to cover the genome of \(M .\) genitalium. Would your ruling for Venter's "organism" be different from Judge Sweet's ruling on patenting of the \(B R C A 1\) and \(B R C A 2\) genes?
What do you think about this solution?
We value your feedback to improve our textbook solutions.